Skip to main content

Table 3 Summary of estimated cases, non-discounted and discounted total costs and life-years of a single age-cohort (n = 25,000) of 12 year old girls

From: Cost-effectiveness of different human papillomavirus vaccines in Singapore

  

Screening only

Bivalent*

Quadrivalent*

Cases

    
 

Cervical cancer

229

32

53

 

Deaths from cervical cancer

144

20

33

 

CIN Persistent 2n3 detected

2,073

294

480

 

CIN 2n3 detected

382

135

168

 

CIN 1 detected

2,109

1,127

1,293

 

Genital warts

4,126

4,126

447

NON-DISCOUNTED

    

Total costs

 

21,150,496

25,020,340

22,822,396

 

Vaccine costs

-

10,000,000

10,000,000

 

Screening costs

11,006,014

9,949,324

10,078,234

 

CIN1 treatment costs

2,330,522

1,245,203

1,292,796

 

CIN 2 & 3 treatment costs

564,776

199,475

247,908

 

CIN Persistent 2 & 3 treatment costs

3,067,301

435,141

710,367

 

Genital warts treatment costs

3,094,714

3,094,714

335,580

 

Cervical cancer treatment costs

1,087,169

96,483

157,511

Life-years (LY)

 

1,692,651

1,695,651

1,695,338

QALYs

 

1,717,089

1,720,571

1,720,299

DISCOUNTED

    

Total costs

 

6,880,106

15,034,926

14,210,399

Life-years (LY)

 

711,164

711,800

711,734

QALYs

 

735,991

736,775

736,784

  1. *In addition to screening